NCT03867682 2023-08-04Venetoclax and Lintuzumab-Ac225 in AML PatientsActinium PharmaceuticalsPhase 1/2 Unknown38 enrolled
NCT05503355 2023-04-04A Phase I/II Dose Escalation and Expansion Study of BST-236 Plus Venetoclax in Patients With Unfit Newly Diagnosed AMLBioSight Ltd.Phase 1/2 Unknown80 enrolled
NCT01211457 2019-07-16Study of Sapacitabine in Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS)Cyclacel Pharmaceuticals, Inc.Phase 1/2 Unknown65 enrolled